Cargando…

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction

Patient satisfaction with glaucoma treatment has been poorly studied to date. Because glaucoma is a chronic condition in which the therapeutic response is dependent on adherence to treatment, patient acceptability is an important factor in achieving satisfactory outcomes. This multicenter, internati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muñoz Negrete, Francisco José, Lemij, Hans G, Erb, Carl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367594/ https://www.ncbi.nlm.nih.gov/pubmed/28356710 http://dx.doi.org/10.2147/OPTH.S126042

Ejemplares similares

Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
por: Erb, Carl, et al.
Publicado: (2021)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Beck, Daniel Edward Robert, et al.
Publicado: (2017)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]
Publicado: (2017)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
por: Harasymowycz, Paul, et al.
Publicado: (2021)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
por: Misiuk-Hojlo, Marta, et al.
Publicado: (2018)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
por: Kim, Joon Mo, et al.
Publicado: (2021)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou, Mario A, et al.
Publicado: (2018)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
por: Tokuda, Naoto, et al.
Publicado: (2017)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi, Matteo, et al.
Publicado: (2014)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo, Hannu, et al.
Publicado: (2016)

Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
por: Seong, Hyo Jin, et al.
Publicado: (2021)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama, Yuko, et al.
Publicado: (2015)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
por: Inoue, Kenji, et al.
Publicado: (2020)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
por: Kim, Dai Woo, et al.
Publicado: (2021)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Katz, Gregory, et al.
Publicado: (2010)

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2016)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
por: Gutierrez-Diaz, Esperanza, et al.
Publicado: (2014)

Cystoid macular edema associated with preservative-free latanoprost after uncomplicated cataract surgery: case report and review of the literature
por: Makri, Olga E., et al.
Publicado: (2017)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops
por: Müllertz, Olivia, et al.
Publicado: (2021)

Correction to: 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2020)

Latanoprost in the treatment of glaucoma
por: Alm, Albert
Publicado: (2014)

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
por: Freiberg, Josefine C., et al.
Publicado: (2022)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
por: Bacharach, Jason, et al.
Publicado: (2023)

Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study
por: Jandroković, Sonja, et al.
Publicado: (2022)

Patient satisfaction with glaucoma therapy: reality or myth?
por: Lemij, Hans G, et al.
Publicado: (2015)

Influence of Latanoprost on Retinal Microcirculation in Glaucoma
por: Kremmer, S, et al.
Publicado: (2014)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial [Corrigendum]
Publicado: (2023)

Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride
por: Liang, H, et al.
Publicado: (2008)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe, Tejaswini, et al.
Publicado: (2016)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

Prostaglandin-associated periorbitopathy in latanoprost users
por: Nakakura, Shunsuke, et al.
Publicado: (2014)

Latanoprost could exacerbate the progression of presbyopia
por: Ayaki, Masahiko, et al.
Publicado: (2019)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
por: Park, Sang-Woo, et al.
Publicado: (2022)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer, Anton, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ln86ckigm9i09ro2a48jrfcrrr